Tapentadol

NUCYNTA

Open Tapentadol in the interactive console ↗

What it isMu-opioid agonist and norepinephrine reuptake inhibitor; severe nociceptive and neuropathic pain.

Why this oneUnlike tramadol, it needs no CYP2D6 activation and has little serotonergic effect, making analgesia more predictable.

What limits itDependence, respiratory depression, and constipation remain. Avoid MAOIs; noradrenergic toxicity and hypertension can result.

FDA-approved for

pain (2008)

FDA label

Read the full label on DailyMed ↗

BOXED WARNING Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant benzodiazepines/CNS depressants.

FDA dosing	Population	Start	Target	Max
Moderate-to-severe acute pain	Adults	Individualized per full PI	Individualized per full PI	Individualized per full PI
Moderate-to-severe acute pain	Pediatric ≥6 yr and ≥40 kg, able to swallow tablets	Individualized per full PI	Individualized per full PI	Individualized per full PI
Moderate-to-severe acute pain, moderate hepatic impairment	Adults	50 mg q8h (max 3 doses/24h)	50 mg q8h	3 doses/24h

Renal Severe renal impairment: not recommended

Hepatic Moderate: 50 mg no more than q8h (max 3 doses/24h); severe: not recommended

Instructions

Take with or without food
Use lowest effective dose for shortest duration
Do not abruptly discontinue in physically dependent patients — taper gradually
Assess need for and consider prescribing naloxone

Contraindications

Significant respiratory depression
Acute or severe bronchial asthma in unmonitored setting or without resuscitative equipment
Known/suspected GI obstruction, including paralytic ileus
MAOIs (concurrently or within 14 days) due to risk of serotonin syndrome

Cautions

Opioid-induced hyperalgesia and allodynia
Serotonin syndrome with concomitant serotonergic drugs
Life-threatening respiratory depression (pulmonary disease, elderly/cachectic/debilitated)
Adrenal insufficiency; severe hypotension
Risk of overdose/death with benzodiazepines or other CNS depressants

Adverse reactions

Nausea
Vomiting
Dizziness
Somnolence
Constipation
Pruritus
Headache
Fatigue

Pregnancy Prolonged use may cause neonatal opioid withdrawal syndrome; may cause fetal harm

Lactation No human data; present in animal milk; monitor breastfed infants for sedation/respiratory depression

⚠ BOXED WARNINGS

Addiction, abuse and misuse
Life-threatening respiratory depression
Risk from concomitant use with benzodiazepines

Cost, est. cash$300–$2,500/month

Generic entry2026

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4

Overdose danger4 / 4

Weight-gain liability0 / 4

Sedation liability2 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityRespiratory depression, dependence and overdose; risk rises sharply with sedatives or impaired clearance.

Mechanism of action: Tapentadol ballicule

Tapentadol ballicule: receptor binding, kinetics and half-life diagram

Open Tapentadol in the interactive console ↗

Memory aids: mascots and interaction avatars

Tapentadol NUCYNTA mascot mnemonic cartoon — **“Tape in the doll’s New scent”**
pinpoint pupils → opioid

OAT substrate

Open Tapentadol in the interactive console ↗